Simon Rushbrook - Concepedia

Author

Simon Rushbrook

Also Known As

Asifabbas Naqvi, Eva Ellinghaus, John Dillon, Mariza de Andrade, Rushbrook, Simon M, S M Rushbrook, S RUSHBROOK, S Rushbrook, S. M. Rushbrook, S. Rushbrook

Publications

6.2K

Citations

H-Index

Concepts

All Affiliations

University of Cambridge Addenbrooke's Hospital Norfolk and Norwich University Hospital Hutchison/MRC Research Centre Newcastle University

About

Simon Rushbrook is an author at University of Cambridge specializing in medicine, hepatology, and pathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	13	14	2.6K
2	Hepatology	11	12	2.5K
3	Gastroenterology	5	5	754
4	Cell Biology	3	3	280
5	Allergy	1	1	251

Simon Rushbrook

Publications

4.3K

Citations

H-Index

Page 1

	Year	Citations
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial Zobair M. Younossi, Vlad Ratziu, Rohit Loomba, The Lancet Interim AnalysisMetabolic Associated SteatohepatitisHepatologyPlacebo-controlled Phase 3Nonalcoholic Fatty Liver Disease	2019	1.2K
Regulatory T Cells Suppress In Vitro Proliferation of Virus-Specific CD8 <sup>+</sup> T Cells during Persistent Hepatitis C Virus Infection Simon Rushbrook, Scott M. Ward, Esther Unitt, Journal of Virology	2005	274
British Society of Gastroenterology and UK-PSC guidelines for the diagnosis and management of primary sclerosing cholangitis Michael H. Chapman, Douglas Thorburn, Gideon M. Hirschfield, Gut Uk-psc GuidelinesDiagnosisPathologyGastroenterologySurgery	2019	272
Compromised lymphocytes infiltrate hepatocellular carcinoma Esther Unitt, Simon Rushbrook, Aileen Marshall, Hepatology	2005	266
Tumour lymphocytic infiltrate and recurrence of hepatocellular carcinoma following liver transplantation Esther Unitt, Aileen Marshall, William Gelson, Journal of Hepatology Tumour Lymphocytic InfiltrateHepatologyMedicineLiver PhysiologyImmunology	2006	254
The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS‐9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis Michael Trauner, Aliya Gulamhusein, Bilal Hameed, Hepatology GastroenterologyPathologyPrimary Biliary CirrhosisCholangiopathiesCholangiocyte Biology	2019	251
Relation between hepatocyte G1 arrest, impaired hepatic regeneration, and fibrosis in chronic hepatitis C virus infection Aileen Marshall, Simon Rushbrook, Susan E. Davies, Gastroenterology HepatologyHepatitis CHepatocyte G1 ArrestViral HepatitisLiver Physiology	2005	201
A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis Kris V. Kowdley, Raj Vuppalanchi, Cynthia Levy, Journal of Hepatology	2020	185
Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score Marco Carbone, Alessandra Nardi, Steve Flack, The Lancet. Gastroenterology & hepatology HepatologyPretreatment PredictionBiliary TractGastroenterologyPrimary Sclerosing Cholangitis	2018	158
Factors Associated With Outcomes of Patients With Primary Sclerosing Cholangitis and Development and Validation of a Risk Scoring System Elizabeth C. Goode, Allan Clark, George Mells, Hepatology	2018	94

Page 1